September 10, 2025Chinese Journal of Applied Physiology

CD3-Bispecific Monoclonal Antibodies: A Novel Therapeutic Approach for Complex and Multifactorial Diseases

View Full Paper

Ask AI

Bookmark

Authors

SSS.P. SINGHLovely Professional University SRSanjesh RathiGujarat University SSSakshi SinghGujarat University

Discussion

Member takes

Implication

This review demonstrates the potential of CD3-bispecific mAbs to improve therapeutic efficacy in cancer immunotherapy, suggesting strategies for enhanced immune activation.

Key Points

CD3-bispecific mAbs lead to T cell-mediated cytotoxicity against target cells, improving treatment options.
Recent drug development examples highlight the therapeutic efficacy of optimizing bispecific monoclonal antibodies.
The review discusses design strategies for CD3-bispecific mAbs aimed at minimizing adverse effects while maximizing efficacy.
Conventional mAbs face limitations that CD3-bispecific mAbs are designed to overcome, amplifying immune responses.

Cite This Study

SINGH et al. (2025) studied this question.

synapsesocial.com/papers/68c24009b210217d64798f9c https://doi.org/10.62958/j.cjap.2025.019

View Full Paper

Ask AI

Bookmark

Implication

This review demonstrates the potential of CD3-bispecific mAbs to improve therapeutic efficacy in cancer immunotherapy, suggesting strategies for enhanced immune activation.

CD3-Bispecific Monoclonal Antibodies: A Novel Therapeutic Approach for Complex and Multifactorial Diseases

Discussion

Member takes

Implication

Key Points

Cite This Study

CD3-Bispecific Monoclonal Antibodies: A Novel Therapeutic Approach for Complex and Multifactorial Diseases

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider